Furthermore, based on the subsequent phase II KEYNOTE-158 basket study (NCT02628067) including a cohort of patients with advanced cervical cancer, pembrolizumab gained FDA approval as a second-line treatment for patients with PD-L1-positive cervical cancer (CPS of ≥1) in 2018 [175,178]. The gene discussed is CD274; the disease is cervical carcinoma.